-
平臺編號：bio-68537
-
國際編號：HB-11601?
-
細胞信息： Ab 21.1
-
規(guī)格：frozen
-
用途：ATCC原裝細胞
-
服務費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
Ab 21.1
運輸方式：凍存運輸
數(shù)量：大量
細胞形態(tài)：淋巴樣
免疫類型：IgG1
生長狀態(tài)：懸浮生長
ATCC Number：HB-11601?
是否是腫瘤細胞：0
物種來源：小鼠
規(guī)格：0.3ml Designations: Ab 21.1
Depositors: ?Aronex Pharmaceuticals Inc.
Isotype: IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human erbB-2 protein
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Comments:Animals were immunized with membrane preparations of NIH3T3 cells engineered to overproduce erbB protein.
Spleen cells were fused with P3X8g8.653 myeloma cells.
The antibody reacts with the extracellular domain of gp185erbB-2.
In vitro and in vivo the antibody has no effect upon N87 cells (an erbB overexpressing human gastric carcinoma).
However, in combination with Ab 23.1 (see ATCC HB-11602 ) in vitro growth of N87 is suppressed and in vivo N87 xenografts can prevented or be caused to regress by a combination of the two antibodies.
The antibodies induces autophosphoryaltion of the gp185erbB-2 protein.
Propagation: ATCC complete growth medium: Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 100 units/ml penicillin and 0.1 mg/ml streptomycin, 74%; NCTC 109 medium, 10%; Hybridoma Cloning Factor, 1%; fetal bovine serum, 15%
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
References: 22128: King CR, et al. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof. US Patent 5,587,458 dated Dec 24 1996
數(shù)量：大量
細胞形態(tài)：淋巴樣
免疫類型：IgG1
生長狀態(tài)：懸浮生長
ATCC Number：HB-11601?
是否是腫瘤細胞：0
物種來源：小鼠
規(guī)格：0.3ml Designations: Ab 21.1
Depositors: ?Aronex Pharmaceuticals Inc.
Isotype: IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human erbB-2 protein
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Comments:Animals were immunized with membrane preparations of NIH3T3 cells engineered to overproduce erbB protein.
Spleen cells were fused with P3X8g8.653 myeloma cells.
The antibody reacts with the extracellular domain of gp185erbB-2.
In vitro and in vivo the antibody has no effect upon N87 cells (an erbB overexpressing human gastric carcinoma).
However, in combination with Ab 23.1 (see ATCC HB-11602 ) in vitro growth of N87 is suppressed and in vivo N87 xenografts can prevented or be caused to regress by a combination of the two antibodies.
The antibodies induces autophosphoryaltion of the gp185erbB-2 protein.
Propagation: ATCC complete growth medium: Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 100 units/ml penicillin and 0.1 mg/ml streptomycin, 74%; NCTC 109 medium, 10%; Hybridoma Cloning Factor, 1%; fetal bovine serum, 15%
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
References: 22128: King CR, et al. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof. US Patent 5,587,458 dated Dec 24 1996
